# NCT06874335 (NCT06874335)

> A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

No report yet. It can be ordered.

- Drugs tested: BHV-1530; BHV-1530 plus cemiplimab
- Indication: advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06874335
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Biohaven Therapeutics Ltd.
- Conditions: Solid Tumor
- Interventions: BHV-1530; Cemiplimab
- Enrollment: 140
- Primary outcome: Dose-escalation and Dose-expansion Cohorts: To determine the safety profile, maximum tolerable dose (MTD), minimally reproducible active dose (MRAD), and recommended dose range (RDR) of BHV-1530 monotherapy and BHV-1530 in combination with cemiplimab
- Primary outcome: Dose-optimization Cohorts: Recommended dose of BHV-1530 for later phase trials

## Indexed commentary on NCT06874335 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06874335
